Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1 2

Status

Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Colorectal Neoplasms 93Stomach Neoplasms 56Rectal Neoplasms 51Colonic Neoplasms 47Pancreatic Neoplasms 21Neoplasms 14Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Adenocarcinoma 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Lymphoma, Large B-Cell, Diffuse 9Cholangiocarcinoma 8Adenocarcinoma Of Esophagus 8Esophageal Neoplasms 5Biliary Tract Neoplasms 5Neurotoxicity Syndromes 4Esophageal Squamous Cell Carcinoma 4Lymphoma, Extranodal NK-T-Cell 3Gastrointestinal Neoplasms 3Gallbladder Neoplasms 3Peritoneal Neoplasms 2Lymphoma 2Liver Neoplasms 2Hepatoblastoma 2Gastrointestinal Diseases 2Colorectal Adenocarcinoma 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Spinocerebellar Degenerations 1

Interventions

pegaspargase 4Oxaliplatin 3Gemcitabine 3Methotrexate 2Etoposide 2Early Intervention, Educational 2Doxorubicin 2Dexamethasone 2sugemalimab 1ferrous sulfate 1ferric gluconate 1Vincristine 1Thalidomide 1Sucrose 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Psychiatric Rehabilitation 1Prednisone 1Pharmacogenomic Testing 1Ketamine 1Drug Therapy 1Darbepoetin alfa 1Cyclophosphamide 1Ciprofloxacin 1Asian ginseng 1Amoxicillin-Potassium Clavulanate Combination 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Extranodal NK-T-Cell × Oxaliplatin × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT02085655 2021-03-15

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Sun Yat-sen University

Phase 3 Unknown
264 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT02359162 2018-05-09

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Sun Yat-sen University

Phase 3 Terminated
50 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡